SciELO - Scientific Electronic Library Online

 
vol.74 número5-6Grado de cumplimiento de la legislación e impartición de enseñanzas anti-tabaco en los centros escolares españolesBrote de gastroenteritis en una residencia de ancianos de Albacete índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

Compartir


Revista Española de Salud Pública

versión On-line ISSN 2173-9110versión impresa ISSN 1135-5727

Resumen

ARROYAVE LOAIZA, Gilma et al. Cost effectiveness of the drug-based treatment of cerebral palsy involving spasticity in Mexico. Rev. Esp. Salud Publica [online]. 2000, vol.74, n.5-6, pp.00-00. ISSN 2173-9110.

Background: Cerebral palsy involving spasticity is a highly handicapping illness, especially among children, the treatment of which is limited to reducing the handicaps involved without any full cure. There is a drug treatment which affords the possibility of providing patients with a better quality of life, regarding which a cost effectiveness analysis is made, note being made of the individual achievements and social benefits. Methods: This analysis is based on nationwide information from Mexico which was obtained from secondary sources. The base data is set out within the framework of trends in the growth of this health problem, and the calculations affording the possibility of sizing up this problem are employed in order to ascertain the benefits thereof based on the following indicators: relative impact of this disease and years of healthy life lost and gained, based on which the social and economic benefit entailed in the drug treatment under analysis is estimated. Results: The data reveals that the drug treatment in question is directly beneficial, because it lowers the relative impact of this disease from 0.92 to 0.40. At the individual level, the greatest benefit takes the form of the improved quality of life among the afflicted children within the 6-12 age range, they having gone from 0.08 years to 0.60 years of life in terms of quality. At the nationwide level, the 595,817 years of healthy life which would be lost without any treatment would be recouped. The monetary value involved in this treatment is that of 2,725.00 Mexican pesos (US $283.00) for administering the drug over a one-year period to each child suffering from this disability Conclusions: This is a low-cost treatment, because it is currently impossible to reverse the neurological and physiological processes of cerebral palsy, this treatment therefore improving the quality of life of the children afflicted with this disease is the best possible benefit. The cost effectiveness analysis taking into account these indicators reveals a clear-cut relationship between the monetary values and the health benefits.

Palabras clave : Cost effectiveness; Cerebral palsy; Spasticity.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons